Pilot Effectivness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34) | PAR 17 271

Frequently Asked Questions (FAQs)

What is the Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34) opportunity?

It is a National Institute of Mental Health (NIMH), National Institutes of Health (NIH) grant program (PAR-17-271) that supports early-stage, real-world oriented pilot effectiveness trials. The focus is on improving longer-term outcomes after a person completes an initial, acute phase of mental health treatment.

What problem is this funding opportunity trying to address?

The opportunity targets the common gap between improvement during acute treatment and the challenges that can follow afterward. Many individuals make progress during initial stabilization or an evidence-based acute treatment episode but later experience lingering symptoms, functional impairment, relapse risk, or difficulty staying engaged with appropriate ongoing services.

What does "post-acute" mean in this funding announcement?

"Post-acute" refers to the period after initial stabilization or after completing an initial evidence-based treatment episode. During this period, clinical goals typically shift away from crisis reduction and toward consolidation of gains, maintenance, and longer-term recovery.

What types of projects is NIMH looking to fund under this R34?

NIMH is looking for pilot effectiveness trials of therapeutic interventions and/or service delivery interventions designed specifically for post-acute management. The intent is to test whether a post-acute intervention or service approach can feasibly and safely help individuals maintain and extend treatment gains over time in real-world settings.

Are both clinical interventions and service delivery approaches allowed?

Yes. The announcement supports pilot effectiveness trials of therapeutic interventions and/or service delivery interventions, as long as they are designed for post-acute management and are tested in a practical, real-world oriented framework.

How should an intervention be matched to the stage of illness?

The intervention should be intentionally matched to stage of illness in two ways: (1) by focus (such as consolidating gains, addressing residual symptoms, improving functioning, preventing relapse, promoting adherence, and guiding appropriate ongoing service use), and (2) by intensity or burden (the time, effort, cost, and complexity required should be appropriate for the problem being targeted and not excessive).

What does NIMH mean by minimizing "burden" in post-acute interventions?

"Burden" refers to the amount of time, effort, cost, and complexity required from participants, families, providers, and systems. NIMH emphasizes that the intensity of the post-acute approach should fit the clinical goals and not impose unnecessary demands relative to the problem being addressed.

Is this grant meant to produce a definitive answer about effectiveness?

No. Because this is an R34 pilot mechanism, the emphasis is not on providing a definitive, large-scale effectiveness conclusion. The goal is to run a well-structured pilot trial that answers practical, real-world questions and generates preliminary data to justify and inform a subsequent larger effectiveness trial (such as a comparative effectiveness study or a practical trial).

What kinds of questions should the pilot trial be able to answer?

The pilot trial is expected to address practical "can this work in the real world?" questions, including whether recruitment, enrollment, retention, and intervention delivery are feasible in the intended setting, and whether the approach is tolerable, acceptable, and safe.

What outcomes or domains should the pilot trial evaluate?

The pilot trial is expected to evaluate feasibility, tolerability, acceptability, and safety (including monitoring for adverse events and unintended harms). It should also generate early signals of potential effectiveness on clinically meaningful outcomes related to post-acute recovery and functioning.

What does "feasibility" mean in the context of this R34 pilot trial?

Feasibility includes whether the team can recruit, enroll, and retain participants, and whether the intervention can be delivered as intended in the target setting.

What does "tolerability" mean for these post-acute interventions?

Tolerability refers to whether participants can reasonably stick with the intervention or service approach without the demands becoming impractical or overly burdensome.

What does "acceptability" mean for this opportunity?

Acceptability addresses whether participants and providers consider the intervention or service approach appropriate, worthwhile, and a good fit for the post-acute stage of care.

What does "safety" cover in the pilot trial expectations?

Safety includes monitoring for adverse events and unintended harms that could result from the intervention or service strategy during the post-acute period.

Why does NIMH emphasize measuring mechanisms or targets, not just outcomes?

NIMH highlights the need to test whether the intervention engages its intended target(s) or mechanism(s) presumed to drive improvement. This means the project should assess whether the intervention is influencing the mediators or processes it claims to influence (for example, adherence behaviors, coping skills, service engagement, or symptom self-management), alongside clinical and functional outcomes.

What are examples of mechanisms or processes the project might assess?

Examples mentioned include adherence behaviors, coping skills, service engagement, symptom self-management, and other mechanisms linked to relapse prevention and sustained functioning.

What is the intended downstream use of results from an R34 pilot under this program?

The expected deliverable is a strong package of feasibility, safety, acceptability, mechanism engagement, and preliminary outcome data that can justify and shape a subsequent, larger trial designed to definitively determine effectiveness for improving longer-term post-acute mental health outcomes.

Which NIH Institute is sponsoring this opportunity?

This opportunity is sponsored by the National Institute of Mental Health (NIMH) within the National Institutes of Health (NIH).

What is the funding category and CFDA number listed for this opportunity?

The opportunity falls under the NIH discretionary grant category and is classified as a health-related funding activity with CFDA 93.242.

What is the listed award ceiling?

The listed award ceiling is $225,000.

Is this opportunity currently open?

The original closing date shown is December 6, 2017, which indicates this particular posting is archived or historical rather than a current open deadline.

Why is an archived posting still useful to review?

Even as a historical cycle, the description provides a model of what NIMH has sought in this area: carefully designed pilot effectiveness trials that bridge controlled efficacy research and larger-scale, real-world effectiveness testing aimed at optimizing longer-term outcomes after acute treatment.

Who is eligible to apply?

Eligibility is broad and includes many types of U.S. public and private organizations. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; and a wide range of nonprofit and for-profit entities (including small businesses).

Are specific institution types explicitly named as eligible?

Yes. The announcement explicitly calls out Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and tribal governments that are not federally recognized, among others.

Can faith-based and community-based organizations apply?

Yes. Faith-based and community-based organizations are explicitly listed among eligible applicant groups.

Are for-profit entities and small businesses eligible?

Yes. A wide range of nonprofit and for-profit entities are eligible, including small businesses.

Can U.S. territories, possessions, or federal agencies apply?

Yes. U.S. territories or possessions and eligible federal agencies are listed among eligible applicant groups.

Are non-U.S. (non-domestic) entities eligible?

Yes. The eligibility list includes non-domestic (non-U.S.) entities.

What kind of team is this opportunity best suited for?

This opportunity is designed for teams that already have a plausible post-acute intervention or service strategy and are ready to test it in a pilot effectiveness framework focused on real-world feasibility, safety, acceptability, mechanism engagement, and early signals of potential effectiveness.

What is the overall goal of the program in one sentence?

To support pilot effectiveness trials of post-acute interventions or service approaches that can feasibly and safely help individuals sustain and build on gains after acute mental health treatment, while generating the preliminary evidence needed for a larger, definitive effectiveness trial.